Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (trading symbol: LPTX) on May 17, 2019. The registrant is a Delaware corporation headquartered in Cambridge, MA, and is classified as an emerging growth company. The report addresses a specific regulatory event regarding its listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses a specific liquidity and equity metric required for regulatory compliance:
- Stockholders' Equity: At least $10.0 million (as of the date of compliance confirmation).
- Debt and Margins: Not disclosed in this filing.
Material Changes and Regulatory Status
The primary material event concerns the company's compliance with Nasdaq listing standards:
- Prior Non-Compliance: On January 24, 2019, the company received notice of non-compliance with the minimum Market Value of Listed Securities requirement (Listing Rule 5450(b)(2)(A)).
- Compliance Period: The company was granted a 180-day period (until July 23, 2019) to regain compliance.
- Resolution: On May 17, 2019, Nasdaq confirmed the company regained compliance by meeting the alternative requirement of maintaining stockholders' equity of at least $10.0 million (Listing Rule 5450(b)(1)(A)).
- Current Status: Nasdaq has officially closed the matter.
- Verify the company's current stockholders' equity remains above the $10.0 million threshold to maintain listing status.
- Review the January 30, 2019 Form 8-K for details on the initial non-compliance notice.
- Confirm the company's continued adherence to other Nasdaq listing requirements (e.g., bid price, market value) not addressed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks beyond the resolution of the listing deficiency. The document confirms the removal of the immediate risk of delisting associated with the January 2019 notice.